Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9955031 | 0.82 | SLC6A2 (0.32) | RPS6KA3RPS6KA2 | |
| SCHEMBL9955205 | 0.82 | RPS6KA3 (0.34) | RPS6KA3RPS6KA2 | |
| SCHEMBL931645 | 0.81 | — | — | |
| SCHEMBL4865636 | 0.76 | KDM5B (0.42) | — | |
| SCHEMBL9954586 | 0.74 | PIK3CB (0.42) | — | |
| SCHEMBL22110830 | 0.73 | — | — | |
| SCHEMBL3561959 | 0.73 | GSK3B (0.46) | — | |
| SCHEMBL9955891 | 0.73 | AR (0.32) | — | |
| SCHEMBL932232 | 0.72 | AR (0.30) | — | |
| SCHEMBL932638 | 0.72 | AR (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655375-B1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | SANOFI SA (FR) | 2014-12-03 | — | — | EP | disclosed |
| US-8815853-B2 | Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2014-08-26 | — | — | US | disclosed |
| US-8815853-B2 | Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2014-08-26 | — | — | US | disclosed |
| US-8815853-B2 | Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2014-08-26 | — | — | US | disclosed |
| US-20130289031-A1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2013-10-31 | — | — | US | disclosed |
| US-20130289031-A1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2013-10-31 | — | — | US | disclosed |
| US-20130289031-A1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2013-10-31 | — | — | US | disclosed |
| EP-2655375-A1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085244-A1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289031-A1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | DPYD, TYMP, DHPS | RPS6KA3 1970/4885RPS6KA2 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.